当前位置： SCI文献检索 > GYNECOLOGIC ONCOLOGY期刊下所有文献 > Long term follow-up of a large series of stage-II/III atypical proliferative serous ovarian tumors.

Long term follow-up of a large series of stage-II/III atypical proliferative serous ovarian tumors.

Abstract：

BACKGROUND:The aim of this study was to assess prognostic factors and implications on further management in a large series of stage-II or III Atypical Proliferative Serous Tumors (APST) with a long-term follow-up. PATIENTS AND METHODS:Patients with APSTs and peritoneal implants treated in, or referred to, our institution were retrospectively reviewed. Prognostic factors on invasive recurrence, disease-free (DFS) and overall survival (OS) were analyzed. RESULTS:Between 1971 and 2017, 212 patients were identified and followed (33 having invasive implants). After a median follow-up of 115 months, 70 recurrences were observed, 28 of them under the form of invasive disease. DFS at 5 years and 10 years was 73% and 62% respectively. The use of a conservative treatment (HR = 5.5[3.33-9.08], p < .0001), the presence of ≥3 peritoneal sites with implants (HR = 1.65[1.01-2.72], p = .045) were unfavorable prognostic factors for DFS. The presence of ≥3 peritoneal sites with implants (HR = 3.02[0.96-9.53], p = .049) and the presence of stromal microinvasion (HR = 3.19[1.12-9.1], p = .022) were unfavorable prognostic factors for OS. Non-conservative surgery (HR = 7[2.35-20.87], p = .0002), invasive implants (HR = 5.37[1.29-22.26], p = .013), and ≥ 3 peritoneal sites with implants (HR = 3.56 [1.11-11.39], p = .024) were identified as predictors of recurrence in the form of an invasive disease. Invasive implants were not associated with DFS (HR = 1.39[0.77-2.51], p = .27), nor OS (HR = 1.76[0.57-5.47], p = .32). CONCLUSION:After a long-term follow-up, type of peritoneal implants is no longer a prognostic factor for OS. Implants ≥3 peritoneal sites seem to impact significantly OS and then require a specific follow-up in this subgroup of patients.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Maria S,Faron M,Maulard A,Pautier P,Leary A,Chargari C,Genestie C,Gouy S,Morice P

doi

10.1016/j.ygyno.2020.06.489

subject

Has Abstract

pub_date

2020-09-01 00:00:00

pages

659-665

issue

3

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(20)32304-0

journal_volume

158

pub_type

杂志文章

相关文献

GYNECOLOGIC ONCOLOGY文献大全
  • Fas-mediated pathway and apoptosis in normal, hyperplastic, and neoplastic endometrium.

    abstract：OBJECTIVES:Abnormalities in the control of cell proliferation and apoptosis have been suggested to contribute to the development and progression of neoplasia. There are at least two pathways that activate apoptosis. The first is a mitochondria-dependent route governed by bcl-2 family proteins. The second is a parallel ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/s0090-8258(03)00411-6

    authors： Atasoy P,Bozdoğan O,Erekul S,Bozdoğan N,Bayram M

    更新日期：2003-11-01 00:00:00

  • Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.

    abstract：OBJECTIVE:This trial determined the efficacy and tolerability of sorafenib and weekly topotecan in patients with platinum-resistant ovarian cancer (OC) or primary peritoneal carcinomatosis (PPC). METHODS:Primary endpoints were maximum tolerated dose of sorafenib with weekly topotecan (phase I) and response rate (phase...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.ygyno.2011.08.033

    authors： Ramasubbaiah R,Perkins SM,Schilder J,Whalen C,Johnson CS,Callahan M,Jones T,Sutton G,Matei D

    更新日期：2011-12-01 00:00:00

  • Treatment of advanced uterine sarcoma with vincristine, actinomycin D, and cyclophosphamide.

    abstract：:Between 1971 and 1979, seventy-four patients with metastatic or advanced recurrent sarcoma of uterine origin were treated with combination chemotherapy consisting of vincristine, actinomycin D, and cyclophosphamide (Cytoxan). The probability of survival at 2 and 5 years was 23 and 15%, respectively. The response rate ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(83)90078-1

    authors： Hannigan EV,Freedman RS,Elder KW,Rutledge FN

    更新日期：1983-04-01 00:00:00

  • The immune response in pregnancy and in cancer is active and supportive of placental and tumor cell growth not their destruction.

    abstract：:While many investigators have described the biochemical and physiological similarities between tumor cells and trophoblast cells, in this discourse we will compare primarily their leucocytes, which constitute a large portion of the tumor and its microenvironment as well as the placenta and its microenvironment. There ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.ygyno.2017.04.019

    authors： Beaman KD,Dambaeva S,Katara GK,Kulshrestha A,Gilman-Sachs A

    更新日期：2017-06-01 00:00:00

  • Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study.

    abstract：:Three hundred sixty-one patients with FIGO stage III and IV ovarian cancer were treated with cis-platinum combination chemotherapy in a Danish multicenter trial. Primary surgery was performed at 58 different departments; 32% of the patients were operated at a department associated with an oncologic center, 50% at a ge...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1016/0090-8258(90)90042-j

    authors： Bertelsen K

    更新日期：1990-08-01 00:00:00

  • Cell kinetics: a prognostic marker in epithelial ovarian cancer.

    abstract：:The proliferative activities (3H-thymidine labeling index, LI) of 72 primary ovarian cancers and 76 metastatic lesions from untreated patients were evaluated. Overall, median LI values for primary and metastatic lesions were similar (7.8 vs 7.0%), but cell kinetics significantly differed in metastases from different s...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/0090-8258(89)90003-6

    authors： Silvestrini R,Daidone MG,Bolis G,Fontanelli R,Landoni F,Andreola S,Colombi R

    更新日期：1989-10-01 00:00:00

  • Screening practices and invasive cervical cancer risk in different age strata.

    abstract：:Relative and population attributable risks for invasive cervical cancer in different age strata relative to screening practices have been estimated using data from a case-control study conducted since 1981 in the greater Milan area, northern Italy. A total of 548 women under 75 years of age with a histologically confi...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(90)90015-d

    authors： Parazzini F,Negri E,La Vecchia C,Bocciolone L

    更新日期：1990-07-01 00:00:00

  • Traditional and nontraditional histopathologic predictors of recurrence in uterine endometrioid adenocarcinoma.

    abstract：:Ninety-three consecutive operative cases of myometrial invasive endometrioid adenocarcinoma of the uterus without evidence of extrauterine spread at surgery were reviewed to determine whether any histopathologic features other than those traditionally reported might predict recurrence. Recurrence was associated with t...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.1994.1158

    authors： Lee KR,Vacek PM,Belinson JL

    更新日期：1994-07-01 00:00:00

  • The Patient Protection and Affordable Care Act: what every provider of gynecologic oncology care should know.

    abstract：:The Patient Protection and Affordable Care Act (ACA) was signed into law by President Barack Obama in 2010. While initial implementation of the law began shortly thereafter, the full implementation will take place over the next few years. With respect to cancer care, the act was intended to make care more accessible, ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.ygyno.2013.02.036

    authors： Duska LR,Engelhard CL

    更新日期：2013-06-01 00:00:00

  • Ovarian steroid cell tumors, not otherwise specified: a case report and literature review.

    abstract：:Steroid cell tumors, not otherwise specified, are rare ovarian sex cord-stromal tumors with malignant potential. The majority of these tumors produce steroids with testosterone being the most common. A case of a 46-year-old woman who presented with sudden onset of virilization and a pelvic mass is reported. Various as...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,评审

    doi：10.1006/gyno.1999.5549

    authors： Reedy MB,Richards WE,Ueland F,Uy K,Lee EY,Bryant C,van Nagell JR Jr

    更新日期：1999-11-01 00:00:00

  • Occult choriocarcinoma discovered by positron emission tomography/computed tomography imaging following a successful pregnancy.

    abstract：BACKGROUND:Positron emission tomography (PET) is commonly used to detect occult or recurrent malignancy, including tumors of the female genital tract. Recently, there have been reports of PET scans used in patients with Gestational Trophoblastic Disease (GTD). CASE:A 22-year-old female presented with vaginal bleeding ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2005.01.049

    authors： Numnum TM,Leath CA 3rd,Straughn JM Jr,Conner MG,Barnes MN 3rd

    更新日期：2005-05-01 00:00:00

  • Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival.

    abstract：OBJECTIVE:To evaluate the survival impact of residual disease at the time of primary surgery for patients with Stage III and IV endometrial carcinoma; to assess morbidity associated with surgical cytoreduction. METHOD:All patients with endometrial carcinoma who underwent primary surgical therapy at the University of M...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2004.03.015

    authors： Lambrou NC,Gómez-Marín O,Mirhashemi R,Beach H,Salom E,Almeida-Parra Z,Peñalver M

    更新日期：2004-06-01 00:00:00

  • Inverse expression of Cdk4 and p16 in epithelial ovarian tumors.

    abstract：OBJECTIVES:The aim of this study was to elucidate the expression and the correlation of two cell cycle regulators, cdk4 and its inhibitor p16, in a series of benign, borderline, and malignant ovarian tumors and to evaluate whether their alterations correlate with clinicopathologial parameters and patients' prognosis in...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.2000.5961

    authors： Sui L,Dong Y,Ohno M,Goto M,Inohara T,Sugimoto K,Tai Y,Hando T,Tokuda M

    更新日期：2000-11-01 00:00:00

  • An immunohistochemical study of colon-ovarian tumor antigen and colon-specific antigen in gynecologic tumors.

    abstract：:The distribution of colon--ovarian tumor antigen (COTA) and colon-specific antigen (CSA) was studied immunohistochemically in gynecologic tumors. The antigens were absent in the serous benign tumors of the ovary and in the normal ovarian tissues, whereas they were detected in some of the mucinous benign tumors. COTA a...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(89)90019-x

    authors： Ueda G,Shimizu C,Saito J,Tanaka Y,Inoue M,Tanizawa O

    更新日期：1989-10-01 00:00:00

  • Survival implications of staging lymphadenectomy for non-endometrioid endometrial cancers.

    abstract：PURPOSE:To determine, in patients with non-endometrioid endometrial carcinoma, 1) survival benefit associated with pelvic lymphadenectomy (LND), 2) survival benefit for para-aortic lymphadenectomy performed in addition to pelvic lymphadenectomy, and 3) association between number of lymph nodes removed and survival. ME...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2018.03.046

    authors： Venigalla S,Chowdhry AK,Shalowitz DI

    更新日期：2018-06-01 00:00:00

  • Disease persistence in patients with cervical intraepithelial neoplasia undergoing electrosurgical conization.

    abstract：OBJECTIVE:Cone margin status has been reported to be the most important predictor of residual disease in patients with cervical intraepithelial neoplasia (CIN) undergoing electrosurgical excisional treatment. The primary aim of this study of patients treated with electrosurgical conization was to evaluate the associati...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.2001.6579

    authors： Costa S,De Nuzzo M,Infante FE,Bonavita B,Marinelli M,Rubino A,Rambelli V,Santini D,Cristiani P,Bucchi L

    更新日期：2002-04-01 00:00:00

  • The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.

    abstract：:MicroRNA molecules are small, single-stranded RNA molecules that function to regulate networks of genes. They play important roles in normal female reproductive tract biology, as well as in the pathogenesis and progression of epithelial ovarian cancer. DROSHA, DICER, and Argonaute proteins are components of the microR...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.ygyno.2017.08.027

    authors： Wang X,Ivan M,Hawkins SM

    更新日期：2017-11-01 00:00:00

  • Association of obesity with survival in patients with endometrial cancer.

    abstract：BACKGROUND:Obesity confers an overall increased risk for development of endometrial cancer. However there are conflicting reports regarding the effect of obesity on patients' overall and disease specific survival. The purpose of this study was to evaluate the effect of obesity on survival in women with endometrial canc...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2019.03.258

    authors： Van Arsdale A,Miller DT,Kuo DY,Isani S,Sanchez L,Nevadunsky NS

    更新日期：2019-07-01 00:00:00

  • Class II radical hysterectomy shows less morbidity and good treatment efficacy compared to class III.

    abstract：:Treatment of 102 patients with cancer of the cervix by class II and III radical hysterectomy was reviewed to compare the operative morbidity and efficacy of class II radical hysterectomy for select cases. Of the 102 patients, 21 had a class II hysterectomy, whereas 81 patients had a class III hysterectomy. The class I...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(91)90078-j

    authors： Photopulos GJ,Zwaag RV

    更新日期：1991-01-01 00:00:00

  • Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach.

    abstract：OBJECTIVE:For many years, BRCA mutational status has only been considered as a predictor of ovarian cancer susceptibility and as a prognostic factor. Nonetheless, in the era of precision medicine, it has also become a predictive biomarker of response to platinum-based-chemotherapy and, more recently, to PARP-inhibitors...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2020.06.479

    authors： Marchetti C,Minucci A,D'Indinosante M,Ergasti R,Arcieri M,Capoluongo ED,Pietragalla A,Caricato C,Scambia G,Fagotti A

    更新日期：2020-09-01 00:00:00

  • A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NR

    abstract：OBJECTIVE:Early-phase data have demonstrated induction of antibody responses to a polyvalent vaccine conjugate (Globo-H, GM2, MUC1-TN, TF) with adjuvant OPT-821. We sought to determine if this combination decreases the hazard of progression or death compared to OPT-821 alone in patients with ovarian cancer in second/th...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.ygyno.2019.09.015

    authors： O'Cearbhaill RE,Deng W,Chen LM,Lucci JA 3rd,Behbakht K,Spirtos NM,Muller CY,Benigno BB,Powell MA,Berry E,Tewari KS,Hanjani P,Lankes HA,Aghajanian C,Sabbatini PJ

    更新日期：2019-12-01 00:00:00

  • TCGA molecular groups of endometrial cancer: Pooled data about prognosis.

    abstract：BACKGROUND:After The Cancer Genome Atlas (TCGA) findings, four novel prognostic groups may direct the management of endometrial cancer (EC): POLE-mutated/ultramutated (POLEmt), microsatellite-instable/hypermutated (MSI), copy-number-low/p53-wild-type (p53wt), and copy-number-high/p53-mutated (p53mt). However, data abou...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,meta分析

    doi：10.1016/j.ygyno.2019.08.019

    authors： Raffone A,Travaglino A,Mascolo M,Carbone L,Guida M,Insabato L,Zullo F

    更新日期：2019-11-01 00:00:00

  • Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3.

    abstract：OBJECTIVE:Different Human Papilloma Virus (HPV) tests are currently used. An integrated comparison of the Amplicor, Cobas4800, PreTect HPV-Proofer and APTIMA HPV tests has not been done. METHODS:We compared the high-risk HPV detection power of these HPV tests in 528 consecutive population-based follow-up Liquid-Based ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2011.07.024

    authors： Ovestad IT,Vennestrøm U,Andersen L,Gudlaugsson E,Munk AC,Malpica A,Feng W,Voorhorst F,Janssen EA,Baak JP

    更新日期：2011-11-01 00:00:00

  • Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis.

    abstract：BACKGROUND:Treatment with weekly cisplatin (CDDP) plus radiotherapy (RT) is the standard regimen for stage IB to stage IVA cervical carcinoma (CC). We performed a systematic review and meta-analysis of published studies to evaluate whether CDDP-based doublet therapy improves survival compared to weekly CDDP plus RT in ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,meta分析,评审

    doi：10.1016/j.ygyno.2014.04.049

    authors： Petrelli F,De Stefani A,Raspagliesi F,Lorusso D,Barni S

    更新日期：2014-07-01 00:00:00

  • Antiemetic treatment of chemotherapy-induced nausea in ovarian carcinoma patients.

    abstract：:In a prospective, randomized, double-blind trial the combination betamethasone-dixyrazine was compared with high-dose metoclopramide as antiemetic treatment during combination chemotherapy (melphalan-doxorubicin and cisplatin) of ovarian carcinoma. Of 40 evaluable patients, 15 (38%) had previous experience with chemot...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/0090-8258(89)90129-7

    authors： Sorbe B,Hallén C

    更新日期：1989-08-01 00:00:00

  • An ultrastructural comparison of grade I and II endometrial adenocarcinoma considering estrogen and progesterone receptor status.

    abstract：:Eighteen (18) previously untreated patients with grade I (9) and II (9) endometrial adenocarcinoma provided endometrial samples for biochemical analysis of estrogen and progesterone receptors. The same samples were evaluated by histology and ultrastructure. Progesterone receptor negative samples (PR less than 1000 fmo...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(84)90022-2

    authors： Horbelt DV,Freedman RS,Roberts DK,Walker NJ,Edwards CL,Jones LA

    更新日期：1984-06-01 00:00:00

  • Strategies in late stage cervix carcinoma.

    abstract：:Stage IIB-IV squamous cell carcinoma of the cervix when treated by irradiation has a significant failure rate. Causes of pelvic and distant failure are discussed. New techniques employed to improve local control and decrease distant metastasis are presented. Data on morbidity, mortality, and survival will be reviewed ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(86)90135-6

    authors： Krochak R

    更新日期：1986-03-01 00:00:00

  • Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.

    abstract：:PARP inhibitors (PARPi) have shown have activity in the treatment of ovarian cancer. Previous studies documented activity in patients with germline (gBRCA) and tumor (tBRCA) BRCA mutations (BRCAm) for treatment in lieu of chemotherapy as well as in recurrent ovarian cancer as maintenance therapy. The recent data from ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2020.07.097

    authors： Pothuri B,O'Cearbhaill R,Eskander R,Armstrong D

    更新日期：2020-10-01 00:00:00

  • A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.

    abstract：OBJECTIVES:Ovarian cancer remains a leading cause of death in women and development of new therapies is essential. Second mitochondria derived activator of caspase (Smac) has been described to sensitize for apoptosis. We have explored the proapoptotic activity of a small molecule mimic of Smac/DIABLO on ovarian cancer ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2007.01.011

    authors： Petrucci E,Pasquini L,Petronelli A,Saulle E,Mariani G,Riccioni R,Biffoni M,Ferretti G,Benedetti-Panici P,Cognetti F,Scambia G,Humphreys R,Peschle C,Testa U

    更新日期：2007-05-01 00:00:00

  • p53 protein overexpression: a strong prognostic factor in uterine papillary serous carcinoma.

    abstract：:Uterine papillary serous carcinoma (UPSC) is an uncommon but aggressive type of endometrial cancer associated with rapid progression of disease and poor prognosis. We investigated 23 cases of UPSC. p53 expression was studied in archival paraffin-embedded tissue by immunohistochemistry. Eleven tumors (47.8%) showed p53...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.1998.5113

    authors： Bancher-Todesca D,Gitsch G,Williams KE,Kohlberger P,Neunteufel W,Obermair A,Heinze G,Breitenecker G,Hacker NF

    更新日期：1998-10-01 00:00:00